At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products

Clinical trials (CTs) provide critical data, which are fundamental to several types of evaluations such as efficacy, effectiveness, and safety of diagnostic tools, medical devices, and the methods ...

[1]  S. Kaehler,et al.  Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria , 2020, Journal of medical economics.

[2]  M. Mamdani,et al.  Estimating the clinical cost of drug development for orphan versus non-orphan drugs , 2019, Orphanet Journal of Rare Diseases.

[3]  J. Nikles,et al.  Barriers for conducting clinical trials in developing countries- a systematic review , 2018, International Journal for Equity in Health.

[4]  A. Amato,et al.  Globalization of clinical trials: ethical and regulatory implications , 2016 .

[5]  M. Demir,et al.  Economic Impact of Clinical Research to Research Centers and Opportunity Cost for the Reimbursement System in Turkey , 2015 .

[6]  C. Tudur Smith,et al.  A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov , 2014, Orphanet Journal of Rare Diseases.

[7]  Li-Jiuan Shen,et al.  Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan. , 2011, Contemporary clinical trials.

[8]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[9]  Charles B Cairns,et al.  Ethical and scientific implications of the globalization of clinical research. , 2009, The New England journal of medicine.

[10]  R. Griggs,et al.  Pivotal studies of orphan drugs approved for neurological diseases , 2009, Annals of neurology.

[11]  S. Chopra.  MSJAMA: Industry funding of clinical trials: benefit or bias? , 2003, JAMA.

[12]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[13]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[14]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[15]  A. Relman,et al.  America's other drug problem: how the drug industry distorts medicine and politics. , 2002, New republic.

[16]  J. LaFleur,et al.  Economic benefits of investigational drug services at an academic institution. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.